Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

Kim, Kyung Hoon; Jang, Byoung Kuk; Chung, Woo Jin; Kweon, Young Oh; Tak, Won Young; Lee, Heon Ju; Lee, Chang Hyeong; Suh, Jeong Ill

doi:10.3350/kjhep.2011.17.3.220

Cited by 12 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al 24 reported SVR rate in the patients at the age of 19-76 with non-genotype 1 HCV infection was 91.4%, while SVR rate of HCV genotype 1 was 66.3%, higher viral load appeared to contribute more to the SVR. However, Kim et al 25 reported HCV genotype 1 and high baseline viral load (HCV RNA >8.0×10 5 IU/mL) were associated with low SVR rate in the patients at the age of 46 to 66. In addition, our results indicated that there was no correlation between SVR and the baseline HCV RNA viral load.…”

Section: Discussionmentioning

confidence: 97%

IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C

Zhong¹,

Zhang²,

Shi³

et al. 2016

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Clinical data on children with chronic hepatitis C (CHC) remain extremely limited. This study investigated sustained virologic response (SVR) to alfa-interferon 2b plus RBV treatment in children aged 1-6 years with unsafe injection-acquired CHC. 154 children with CHC aged 1 to 6 years were enrolled, 101 of them were male (65.6%) and 53 were female (34.4%), and they were treated with alfa-interferon at a dose of 1-5 MIU/m2 3 times weekly plus oral RBV (15 mg/kg/day) for 48 weeks. 57(39.3 %) of them were genotype 1b, 73(50.3%) were genotypes 2a, 15(10.3%) were undecided type. SVR was achieved in 53 of 57(93.0%) patients with genotype 1b, in 72 (98.6%) of 73 with genotype 2a, 15(100.0%) of 15 with undecided type. There was no significant statistical difference in SVR between male and female (98.0% vs 94.3%, p=0.340), genotype 2a and those with genotype 1b(98.6% vs 93.0%, p=0.160), ALT>40U/L group and ALT≤40U/L group(96.7% vs 96.8%, p=1.000), AST>40U/L group and AST≤40U/L group(95.9% vs 98.2%, p=0.654) as well as lower baseline viral load group (<6×105 IU/ml) and higher baseline viral load group(≥6×105 IU/ml)(97.3% vs 95.3%, p=0.916). Leucopenia, neutropenia, hemoglobin concentration decrease, fever, platelet count decrease and rash were 8.4%, 69.5%, 24.0%, 50.6%, 1.9% and 4.5%, respectively. And only 12(7.8%) individuals developed thyroid autoantibodies. The SVR was higher in patients with IL-28B genotype C/C than C/T (99.0% vs 80%, p=0.002). Compared with HCV viral genotype, ALT level and baseline viral load, IL-28B rs12979860 is more suitable for predicting antiviral efficacy in children with CHC. It is inappropriate to take the increase of ALT level as an essential indicator for antiviral treatment in children aged 1-6 years.

show abstract

Section: Discussionmentioning

confidence: 97%

IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C

Zhong¹,

Zhang²,

Shi³

et al. 2016

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…In a recent study of South Korean patients diagnosed with liver cirrhosis clinically that received peginferferon and ribavirin combination therapy, SVR rates were reported to be 20.8% for genotype 1 patients and 52.6% for genotype 2 or 3 patients 20. In the multivariate analysis, HCV genotype 1 is an independent factor associated with low SVR rates 20.…”

Section: Discussionmentioning

confidence: 99%

“…In the multivariate analysis, HCV genotype 1 is an independent factor associated with low SVR rates 20. It is generally well-known that chronic hepatitis C patients without cirrhosis have low SVR rates if they have HCV genotype 1 and a high viral load prior to treatment 20.…”

Section: Discussionmentioning

confidence: 99%

Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients

et al. 2013

Self Cite

View full text Add to dashboard Cite

Background/AimsChronic hepatitis C patients with advanced fibrosis have unsatisfactory sustained virological response (SVR) rates. Few data demonstrating the efficacy of combination therapy in chronic hepatitis C patients with advanced fibrosis in South Korea are available. The purpose of this study was to assess whether the stage of fibrosis impacts the efficacy of combination therapy for chronic hepatitis C.MethodsWe retrospectively reviewed data for a total of 109 patients with chronic hepatitis C, treated with peginterferon alfa and ribavirin. SVR according to the stage of liver fibrosis assessed by pretreatment liver biopsy and genotype results were analyzed.ResultsData from 66 genotype 1 patients (60.6%) and 43 genotype 2 or 3 patients (39.4%) among the 109 patients were analyzed. SVR rates for the genotype 1 patients were significantly lower for the stage 3-4 group (32.1%) than the stage 0-2 group (78.9%; P<0.001). SVR rates (92.0% for stage 0-2, 77.8% for stage 3-4, P=0.184) of genotype 2 or 3 patients were not significantly different according to fibrosis stage. Likewise, the frequency of adverse events was not significantly different according to fibrosis stage.ConclusionsCompared to patients without advanced fibrosis, we can anticipate good SVR rates for genotype 2 or 3 patients with advanced fibrosis and they did not show an inferior tolerability for peginterferon and ribavirin combination therpy. Our results suggest that active treatment is needed for genotype 2 or 3 patients with advanced fibrosis.

show abstract

“…Therefore, there is an urgent need for predictive genetic tools such as those based on SNP profiling (referred as personalized medicine), to characterize patients with susceptibility to HCV infection and HCV-mediated liver diseases. This will allow for better predictions in HCV infection progression rates and improvements in the outcome of standard therapies involving pegylated IFN- α combined with ribavirin [24]. TLR3, a sensor of the host immune system activated by viral dsRNA and responsible for the production of IFN, has been demonstrated to play an essential role during HCV infection and clearance, as well as in the severity of liver diseases.…”

Section: Discussionmentioning

confidence: 99%

Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection

Al-Anazi

Matou‐Nasri

Abdo

et al. 2017

Journal of Immunology Research

View full text Add to dashboard Cite

Toll-like receptor 3 (TLR3) plays a key role in innate immunity by recognizing pathogenic, double-stranded RNAs. Thus, activation of TLR3 is a major factor in antiviral defense and tumor eradication. Although downregulation of TLR3 gene expression has been mainly reported in patients infected with hepatitis C virus (HCV), the influence of TLR3 genotype on the risk of HCV infection, HCV-related cirrhosis, and/or hepatocellular carcinoma (HCC) remains to be determined. Single-nucleotide polymorphisms (SNPs) within the TLR3 gene and their associations with HCV-related disease risk were investigated in a Saudi Arabian population in this study. Eight TLR3 SNPs were analyzed in 563 patients with HCV, which consisted of 437 patients with chronic HCV infections, 88 with HCV-induced liver cirrhosis, and 38 with HCC. A total of 599 healthy control subjects were recruited to the study. Among the eight TLR3 SNPs studied, the rs78726532 SNP was strongly associated with HCV infection when compared to that in healthy control subjects. The rs5743314 was also strongly associated with HCV-related liver disease progression (cirrhosis and HCC). In summary, these results indicate that distinct genetic variants of TLR3 SNPs are associated with HCV infection and HCV-mediated liver disease progression in the Saudi Arabian population.

show abstract

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

Cited by 12 publications

References 18 publications

IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C

IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C

Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients

Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection

Contact Info

Product

Resources

About